IL-17E synergizes with EGF and confers in vitro resistance to EGFR-targeted therapies in TNBC cells

Estrogen receptor-, progesterone receptor- and HER2-negative breast cancers, also known as triple-negative breast cancers (TNBCs), have poor prognoses and are refractory to current therapeutic agents, including epidermal growth factor receptor (EGFR) inhibitors. Resistance to anti-EGFR therapeutic a...

Descripción completa

Detalles Bibliográficos
Autores principales: Merrouche, Yacine, Fabre, Joseph, Cure, Herve, Garbar, Christian, Fuselier, Camille, Bastid, Jeremy, Antonicelli, Frank, Al-Daccak, Reem, Bensussan, Armand, Giustiniani, Jerome
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5288192/
https://www.ncbi.nlm.nih.gov/pubmed/27462789
http://dx.doi.org/10.18632/oncotarget.10804

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5288192/
https://www.ncbi.nlm.nih.gov/pubmed/27462789
http://dx.doi.org/10.18632/oncotarget.10804

Ejemplares similares